News | Proton Therapy | June 24, 2021

Huntsman Cancer Institute Begins Treatment with Mevion Compact Proton Therapy System

 Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11 with the MEVION S250i Proton Therapy System.

The teams from HCI, U of U and Mevion gather to celebrate the center’s grand opening. Group from left to right: Bill Salter, Ph.D., Senior Director of Radiation Oncology, HCI and Professor and Chief of the Division of Medical Physics, U of U -- Robyn Walker, Sr. Director, Customer Success and Service Operations, Mevion -- James Cooley, Ph.D., Director of Advanced Development, Mevion -- Dennis Shrieve, M.D., Ph.D., Chair in Cancer Research, HCI and Chair of Department of Radiation Oncology, U of U -- Tina Yu, Ph.D., CEO, Mevion -- Michael Good, M.D., Interim President, U of U and Sr. VP for Health Sciences, U of U Health -- Ying Hitchcock, M.D., Professor and Medical Director, Department of Radiation Oncology, U of U. (Photo: Business Wire)

June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11 with the MEVION S250i Proton Therapy System. Despite the challenges of the COVID-19 pandemic, the Mevion team successfully installed the MEVION S250i in 7 months from the delivery of the accelerator.

HCI is the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serves a geographic region that includes all of Utah, Idaho, Montana, Nevada, and Wyoming.

“After more than a decade of monitoring and evaluating the evolution of proton therapy technology, along with the needs of our patients, we are excited to officially launch our proton center and to provide this extraordinary treatment option to our patients,” said Bill Salter, Ph.D., Senior Director of Radiation Oncology at HCI and Professor and Chief of the Division of Medical Physics at the U of U. “Our initial experience of treating both adult and pediatric tumors has already made evident the unique clinical capabilities of proton technology.”

The center features Mevion’s industry leading HYPERSCAN pencil beam scanning technology and Adaptive Aperture pMLC. The powerful duo provides faster and more precise dose delivery and minimizes damage to surrounding healthy tissue and sensitive organs at risk. HCI has also integrated a diagnostic CT on-rail system and a surface-guidance tracking system, enabling a state-of-art Image-Guided Proton Therapy (IGPT) configuration to align and treat patients with the upmost accuracy.

Thanks to the reduced size and complexity of the MEVION S250i, the HCI Center for Proton Therapy was placed in a small available space alongside HCI’s existing radiation therapy department. This significantly decreased the project construction and operation cost and allows the cancer center to share existing resources and give patients access to all of HCI’s cancer treatment and research offerings under one roof.

“It is to our greatest pleasure that the underserved patients in the Mountain West now have access to proton therapy,” said Tina Yu, Ph.D., chief executive officer of Mevion Medical Systems. “We are honored to partner with HCI to make this happen and look forward to our many years of collaboration and research to further advance this superior treatment modality.”

As the leading supplier of compact proton therapy systems in the United States, Mevion has been selected by more leading cancer centers, including NCI-Designated Cancer Centers, and has treated over 6,000 patients worldwide.

For more information: www.mevion.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.